Colin Broom, BSc, MB BS, MRCP, FFPM
Dr. Broom has been our CEO since September 2019. Over the past 30 years he has been involved in all stages of drug development and commercialization across multiple therapeutic areas including oncology, anti-infectives and pulmonary medicine. He served as CEO of Nabriva Therapeutics plc until July 2018 and remains a member of the Board of Directors. Previously he was Chief Scientific Officer at ViroPharma Inc. until its acquisition by Shire in 2014 and was a member of the Board of NPS Pharmaceuticals. Previous positions include a range of international leadership roles with Amgen, SmithKline Beecham and Glaxo (now Glaxo SmithKline). He has a BSc in Pharmacology from University College, London and received his medical degree and clinical training at St George’s Hospital Medical School in London. He is a member of the Royal College of Physicians of the UK and a fellow of the Faculty of Pharmaceutical Medicine.
LEO LINBECK, III
Mr. Linbeck has been our Chairman for more than a decade, and recently served as our Executive Chairman until September 2019. He is CEO of Aquinas Companies, a private, diversified holding company with annual revenues in excess of $300 million. He is Founder and Chairman of Fannin Innovation Studio, Houston’s most active life science technology development company. Under his leadership, Fannin has launched more than 15 companies and raised dilutive and non-dilutive funding of more than $125 million. He is one of the inventors of the Brevitest diagnostic system, and holds a number of patents. He serves on the board of Procyrion, a clinical-stage medical device company and is interim President of Raptamer Discovery Group, a next-generation aptamer development company. He has been on the faculty of Stanford Graduate School of Business since 2005 and is active in a number of political and philanthropic organizations.
MAGNUS HÖÖK, PHD
A Director of Pulmotect and a Regents Professor at the Institute of Biosciences and Technology of Texas A&M, where he is the Director of the Center for Infection and Inflammation. Dr. Höök was recognized in 2005 as one of the top 5% funded scientist from the NIH for the past 25 years. Dr. Hook is an inventor and co-founder of Pulmotect. He is also a co-founder of Inhibitex, Inc., a publicly traded company. He has served on scientific advisory boards of several companies.
ATUL VARADHACHARY, MD, PHD
A Director of Pulmotect and the Managing Partner of Fannin Innovation Studio. Dr. Varadhachary brings over two decades of experience in life sciences and healthcare in both corporate and entrepreneurial settings. Previously he served as President of U.S. Operations at Reliance Life Sciences (RLS), part of the Reliance Group, India’s largest private sector enterprise with over $64 billion in annual revenues and for nine years as President & COO of Agennix, Inc., a late-stage biotechnology company where he helped lead a successful sale of the company. He also served as Senior Engagement Manager at the global management consulting firm, McKinsey & Co. He has served on the Board of Managers of the Harris Health System and as an Adjunct Professor at the Baylor College of Medicine and at the Jones Graduate School of Management at Rice University. He serves on the Life Sciences Advisory Committee of the Houston Technology Center, on the board of Reliance Life Sciences. and has served on the University of Houston Biotechnology Industrial Advisory Committee.
BRUCE GIVEN, MD
A Director of Pulmotect, Dr. Given is COO of Arrowhead Research, Inc. (Nasdaq: ARWR)and CEO of Leonardo Biosystems. Dr. Given recently retired as Chairman of the Board for ICON, plc (Nasdaq: ICLR). Until June of 2007, Dr. Given served as President and Chief Executive Officer and as a member of the Board of Directors of Encysive Pharmaceuticals. Previously he was with Johnson & Johnson for 9 years, serving in several capacities including President, International, Ortho-Clinical Diagnostics and as Group Vice President, Head of U.S. Marketing & Sales, Research & Development for Janssen Pharmaceutica. He has also held various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute and Schering-Plough Corporation. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago.
MARK BENEDYK, PHD
A Director of Pulmotect, Dr. Benedyk has over 20 years of experience as a business development executive and consultant to life science companies. He previously headed The Pfizer Incubator (TPI) in La Jolla, CA where he held board positions with TPI and its portfolio companies, reviewed investment opportunities for the Incubator, and oversaw the TPI operations team. Before that, he held executive positions in Business Development and Intellectual Property at Ascenta Therapeutics, Optimer Pharmaceuticals (now Merck (NYSE: MRK)), Aurora Biosciences (now Vertex (NASDAQ: VRTX)) and Elan Pharmaceuticals (now Perrigo (NYSE: PRGO)). In addition, Dr. Benedyk founded and managed Rila Partners LLC, a life sciences strategy and business development advisory firm serving specialty care biotechnology companies. Dr. Benedyk received a PhD in Developmental Genetics from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow. He received his BS in Microbiology and Botany from the University of Michigan.
Kumar Srinivasan, PHD
A Director of Pulmotect, Kumar Srinivasan joined AstraZeneca in April 2012 and as of August 2019, Kumar assumed a new role as Vice President and Global Head of Business Development and Licensing, BioPharmaceuticals R&D, AstraZeneca. In his most recent external position, Kumar was Chief Business Officer at Probiodrug AG, then a private venture-funded German company developing novel treatments for Alzheimer’s disease and inflammatory diseases. Prior to joining Probiodrug, Kumar was Vice President, Global Business Development at Wyeth Pharmaceuticals, where he headed up business development and licensing activities for pre phase 2 opportunities for several therapeutic areas. Kumar has a Ph.D from Case Western University in chemistry, did his postdoctoral work at Caltech and has an MBA from the University of Chicago’s Booth School of Business.